Carlo Cattrini

16PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunityCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Apr 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.

Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud

|Apr 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.

Sebastiano Buti, Alessandro Olivari, Cristina Masini

|Jul 26, 2023
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.

Chiara Tommasi, Giulia Scartabellati, Diana Giannarelli

|Aug 17, 2022
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".

Carlo Cattrini, Carlo Messina, Alessia Mennitto

|Apr 12, 2022
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.

Carlo Cattrini, Orazio Caffo, Ugo De Giorgi

|Nov 22, 2021
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis.

Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi

Pageof 3

Frequent Collaborators

5 joint publications

Melissa Bersanelli

3 joint publications

Elena Castro

3 joint publications

Sebastiano Buti

2 joint publications

Paola Barboro